Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- “Vaccine Gap” in Japan Needs Immediate Resolution: Prof. Plotkin
December 13, 2010
- Develop More Drugs for Cancer, Hereditary Diseases: Mr Inoue
December 13, 2010
- Pharma Eight Starts New Drug Seeds Discovery in Okinawa
December 13, 2010
- Sanofi-aventis Completes Collection of PMS Case Report Forms for Lantus
December 13, 2010
- PMDA to Upgrade Reviewers' Scientific Expertise
December 6, 2010
- Astellas to Increase Market Share for Vesicare with OD Tablets
December 6, 2010
- No. of Generics Listed in November Announced by Korosho
December 6, 2010
- Inavir Can Complete Treatment with a Single Dose: Daiichi Sankyo
December 6, 2010
- PMDA's Project Team Proposes East Asian Central Review System
December 6, 2010
- Novartis to Globally Apply for 13 Drugs in 2011, 9 in 2012
December 6, 2010
- Approval of Two Implantable Heart Assist Systems Recommended
December 6, 2010
- Toho Expects One Point Reduction in Yakkasa on Full-Year Basis
December 6, 2010
- Ono Aims at Sales of ¥10 Bil. for Emend
December 6, 2010
- Need for Closer Cooperation Reconfirmed at 4th THMM
December 6, 2010
- Major Dispensing Pharmacy Chains Introduce More Automatic Dispensing Systems
December 6, 2010
- EPS: Sales Up 25% Driven by CSO Business
December 6, 2010
- Efficacy Not Confirmed for NV1FGF in PIII: AHA
December 6, 2010
- Use of Points for Out-of-Pocket Payments Unacceptable: JPA
December 6, 2010
- Safety, Efficacy of Anacetrapib Confirmed in PIII: AHA
December 6, 2010
- Novartis, sanofi-aventis to Copromote Equa
December 6, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…